ANGELA LONG: Open Payments
NPI 1962824086 · ENID, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$671 in 29 payments from 13 companies in 2025. Trend: 2023 $722 · 2024 $872 · 2025 $671
Food & beverage: $671
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $165 |
| AstraZeneca Pharmaceuticals LP | 4 | $88 |
| GENZYME CORPORATION | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $64 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| Phadia US Inc. | 1 | $24 |
| CSL Behring | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $21 |
Products named: DUPIXENT, Rhapsido, FASENRA, CUVITRU, NEFFY, ImmunoCAP, Hizentra, NUCALA.
Industry payments across OK — which companies pay providers there.
